Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 2
1997 7
1998 23
1999 38
2000 51
2001 62
2002 60
2003 81
2004 89
2005 79
2006 93
2007 88
2008 94
2009 102
2010 88
2011 82
2012 71
2013 103
2014 97
2015 61
2016 69
2017 79
2018 101
2019 54
2020 72
2021 57
Text availability
Article attribute
Article type
Publication date

Search Results

1,625 results
Results by year
Filters applied: . Clear all
Page 1
Montelukast-induced adverse drug reactions: a review of case reports in the literature.
Calapai G, Casciaro M, Miroddi M, Calapai F, Navarra M, Gangemi S. Calapai G, et al. Pharmacology. 2014;94(1-2):60-70. doi: 10.1159/000366164. Epub 2014 Sep 2. Pharmacology. 2014. PMID: 25196099 Free article. Review.
Several clinical trials emphasized that montelukast can be considered a safe drug. However, recent evidence reconsidered the benefit/risk ratio of the use of montelukast for both paediatric and adult patients. ...A better understanding of the mechanisms causing ADRs …
Several clinical trials emphasized that montelukast can be considered a safe drug. However, recent evidence reconsidered the benefit/ …
Montelukast for prevention and treatment of asthma exacerbations in adults: Systematic review and meta-analysis.
Zhang HP, Jia CE, Lv Y, Gibson PG, Wang G. Zhang HP, et al. Allergy Asthma Proc. 2014 Jul-Aug;35(4):278-87. doi: 10.2500/aap.2014.35.3745. Allergy Asthma Proc. 2014. PMID: 24992547 Review.
In acute asthma, montelukast could statistically improve peak expiratory flow percent predicted (p = 0.008) and reduce systemic corticosteroid intake (p = 0.005). Montelukast had low risk in hoarseness and insomnia. Our meta-analysis suggests that montelukast
In acute asthma, montelukast could statistically improve peak expiratory flow percent predicted (p = 0.008) and reduce systemic corti …
A meta-analysis of montelukast for recurrent wheeze in preschool children.
Hussein HR, Gupta A, Broughton S, Ruiz G, Brathwaite N, Bossley CJ. Hussein HR, et al. Eur J Pediatr. 2017 Jul;176(7):963-969. doi: 10.1007/s00431-017-2936-6. Epub 2017 Jun 1. Eur J Pediatr. 2017. PMID: 28567533 Free PMC article. Review.
The pooled results of the continuous regimen showed no significant difference in the number of wheezing episodes between the montelukast and placebo groups (MD -0.40, 95% CI -1.00 to 0.19; mean for montelukast 2.05 vs placebo 2.37 (p = 0.18)). ...What is Known: Curr …
The pooled results of the continuous regimen showed no significant difference in the number of wheezing episodes between the montelukast
Montelukast and Neuropsychiatric Events in Children with Asthma: A Nested Case-Control Study.
Glockler-Lauf SD, Finkelstein Y, Zhu J, Feldman LY, To T. Glockler-Lauf SD, et al. J Pediatr. 2019 Jun;209:176-182.e4. doi: 10.1016/j.jpeds.2019.02.009. Epub 2019 Mar 21. J Pediatr. 2019. PMID: 30905424
OBJECTIVE: To examine the association between montelukast prescription and neuropsychiatric events in children with asthma. ...Cases were matched to up to 4 controls on birth year, year of asthma diagnosis, and sex. The exposures were dispensed prescriptions for montelu
OBJECTIVE: To examine the association between montelukast prescription and neuropsychiatric events in children with asthma. ...Cases …
Psychiatric Disorders and Montelukast in Children: A Disproportionality Analysis of the VigiBase().
Aldea Perona A, García-Sáiz M, Sanz Álvarez E. Aldea Perona A, et al. Drug Saf. 2016 Jan;39(1):69-78. doi: 10.1007/s40264-015-0360-2. Drug Saf. 2016. PMID: 26620206
CONCLUSIONS: Neuropsychiatric disorders as side effects of montelukast were more frequently reported for children than for adults. ...Practitioners should be aware of the risk of neuropsychiatric events associated with montelukast use, and should advise the patient …
CONCLUSIONS: Neuropsychiatric disorders as side effects of montelukast were more frequently reported for children than for adults. .. …
Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial.
Mahatme MS, Dakhale GN, Tadke K, Hiware SK, Dudhgaonkar SD, Wankhede S. Mahatme MS, et al. Indian J Pharmacol. 2016 Nov-Dec;48(6):649-653. doi: 10.4103/0253-7613.194854. Indian J Pharmacol. 2016. PMID: 28066101 Free PMC article. Clinical Trial.

The mean change of TNSS, i.e., 9.46 was significant (P < 0.05) in montelukast-fexofenadine group. The cost-effectiveness ratio was less in montelukast-levocetirizine group than in montelukast-fexofenadine group. CONCLUSION: The decrease in TNSS was more in

The mean change of TNSS, i.e., 9.46 was significant (P < 0.05) in montelukast-fexofenadine group. The cost-effectiveness ratio was

Effect of Montelukast on Bronchopulmonary Dysplasia (BPD) and Related Mechanisms.
Chen X, Zhang X, Pan J. Chen X, et al. Med Sci Monit. 2019 Mar 13;25:1886-1893. doi: 10.12659/MSM.912774. Med Sci Monit. 2019. PMID: 30862773 Free PMC article.
Currently, the efficacy and safety of montelukast sodium in treating BPD has been revealed, however, the precise molecular mechanism of the effect of montelukast on BPD development remain largely unclear. Therefore, this study aimed to investigate the effect and mec …
Currently, the efficacy and safety of montelukast sodium in treating BPD has been revealed, however, the precise molecular mechanism …
The efficacy and safety of H1-antihistamine versus Montelukast for allergic rhinitis: A systematic review and meta-analysis.
Wei C. Wei C. Biomed Pharmacother. 2016 Oct;83:989-997. doi: 10.1016/j.biopha.2016.08.003. Epub 2016 Aug 11. Biomed Pharmacother. 2016. PMID: 27522261 Review.
METHODS: We searched the databases of Pubmed, the Cochrane Library, Nature and Science as well as Wanfang data and CNKI from 2000 to March 2016, using key words "Montelukast SAH" or "H1-antihistamine Montelukast", or "Loratadine Montelukast", or "Desloratadin …
METHODS: We searched the databases of Pubmed, the Cochrane Library, Nature and Science as well as Wanfang data and CNKI from 2000 to March 2 …
Montelukast.
Markham A, Faulds D. Markham A, et al. Drugs. 1998 Aug;56(2):251-6; discussion 257. doi: 10.2165/00003495-199856020-00010. Drugs. 1998. PMID: 9711449 Review.
Montelukast is a selective antagonist of the leukotriene D4 (LTD4) receptor. ...Montelukast (5 mg/day) has also demonstrated efficacy in childhood asthma. ...
Montelukast is a selective antagonist of the leukotriene D4 (LTD4) receptor. ...Montelukast (5 mg/day) has also demonstrated e
In vitro cytotoxicity of montelukast in HAPI and SH-SY5Y cells.
Tseng YT, Cox TM, Grant GD, Arora D, Hall S, McFarland AJ, Ekberg J, Rudrawar S, Anoopkumar-Dukie S. Tseng YT, et al. Chem Biol Interact. 2020 Aug 1;326:109134. doi: 10.1016/j.cbi.2020.109134. Epub 2020 May 25. Chem Biol Interact. 2020. PMID: 32464120
This study aimed to investigate whether montelukast can induce neuroinflammation and neurotoxicity in microglial HAPI cells and neural SH-SY5Y cells. ...The current study highlights the importance of consideration between benefit and risk of montelukast usage and pr …
This study aimed to investigate whether montelukast can induce neuroinflammation and neurotoxicity in microglial HAPI cells and neura …
1,625 results